Abstract
The prediction, prevention, and management of infectious diseases in the United States is either geographically homogeneous or is coordinated through ad-hoc administrative regions, ignoring the intense spatio-temporal heterogeneity displayed by most outbreaks. Using influenza as a case study, we characterize a regionalization of the United States. Based on influenza time series constructed from fine-scale insurance claims data from 2002-2009, we apply a complex network approach to characterize regions of the U.S. which experience comparable influenza dynamics. Our results identify three to five epidemiologically distinct regions for each flu season, with all locations within each region experiencing synchronous epidemics, and with an average of a two week delay in peak timing between regions. We find that there is significant heterogeneity across seasons in the identity of the regions and the relative timing across regions, making predictability from one season to the next challenging. Within a given season, however, our approach shows the potential to inform on the shaping of regions over time, to improve resources mobilization and targeted communication. Our epidemiologically-driven regionalization approach could allow for disease monitoring and control based on epidemiological risk rather than geopolitical boundaries, and provides a tractable public health approach to account for vast heterogeneity that exists in respiratory disease dynamics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Jayne Koskinas and Ted Giovanis Foundation for Health and Policy; the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and TechnologyDirectorate, Department of Homeland Security (DHS), and the Fogarty International Center, National Institutes of Health (NIH); and by the National Institute of General Medical Sciences of the NIH under AwardNumber R01GM123007. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient records and information in the medical claims dataset were anonymized, deidentified, and aggregatedby SDI Health. All analyses were performed with aggregated time series data for influenza-like illness ratherthan patient-level information. Ethical review was sought from the Institutional Review Board at Georgetown University and was deemed exempt
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data associated with this study are provided in a GitHub repository:
